- Details
- Pedro Barata and María Bourlon discuss the CheckMate 9ER trial's 55-month follow-up, revealing the enduring benefits of cabozantinib plus nivolumab over sunitinib in untreated advanced renal cell carcinoma. The trial highlights significant advancements in overall survival, progression-free survival, and response rates, alongside improved quality of life for patients. Dr. Bourlon emphasizes the tri...
|
- Details
- Pedro Barata engages in a discussion with Martin Voss about volrustomig, a novel PD-1/CTLA-4 bispecific antibody for advanced clear cell RCC. Dr. Voss provides an overview of volrustomig, highlighting its unique ability to inhibit PD-1 and selectively bind CTLA-4 on cells co-expressing both receptors, aiming for targeted action in the tumor microenvironment. He reviews the dose-finding study's pro...
|
- Details
- Pedro Barata engages in a conversation with Dan George about developments in kidney cancer treatments from the ESMO conference. Their discussion centers on the EVEREST trial, which investigates the use of the mTOR inhibitor everolimus in an adjuvant setting for high-risk kidney cancer patients post-nephrectomy. Dr. George emphasizes the significance of targeting high-risk patients, particularly th...
|
- Details
- Neeraj Agarwal discusses the phase two LITESPARK-013 trial exploring the efficacy of belzutifan, a hypoxia-inducible transcription factor 2 alpha inhibitor, in treating metastatic renal cell carcinoma. The trial compares two doses of belzutifan (120 milligrams and 200 milligrams daily) in patients who have progressed on PD-1 axis inhibitors. The primary endpoint is the objective response rate, wit...
|
- Details
- Pedro Barata speaks with Kathryn Beckermann regarding a groundbreaking Phase I/IIb trial she presented at ASCO. This trial explored the use of a new AXL inhibitor, in conjunction with cabozantinib and nivolumab, for advanced Renal Cell Carcinoma (RCC). Dr. Beckermann elucidates the rationale behind targeting the Gas6 AXL pathway, known for its upregulation in kidney cancer and its role as a resist...
|
- Details
- Pedro Barata and Ritesh Kotecha discuss a study examining genetic ancestry and molecular correlations in kidney cancer patients. Dr. Kotecha outlines the comprehensive approach taken to genomic testing, including both somatic and germline testing. Highlighting their cohort of over 900 patients, they discuss the collection and analysis of genomic information. Dr. Kotecha elucidates their use of gen...
|
- Details
- In this discussion, Chung-Han Lee delves into his significant contributions to kidney cancer research. Dr. Lee's studies, particularly the KEYNOTE-B61 clinical trial involving non-clear cell renal cell carcinoma patients, are celebrated for their potential to revolutionize treatment practices. This specific trial evaluated the combination of lenvatinib and pembrolizumab and demonstrated a 49% resp...
|
- Details
- Pedro Barata speaks with Nazli Dizman regarding her work on a Phase I trial involving immunotherapies and gut microbiome in metastatic renal cell carcinoma. Dr. Dizman discusses the rationale behind the study, highlighting the increasing recognition of gut microbiome's impact on disease processes, including cancer. The trial tested CBM588, a bacterium used in Japan for over 50 years, which was exp...
|
- Details
- Pedro Barata converses with Andrew Hahn about his work in kidney cancer research. They delve into Dr. Hahn's study on cytoreductive nephrectomy for patients with metastatic sarcomatoid or rhabdoid renal cell carcinoma (RCC) undergoing immunotherapy-based regimens. Dr. Hahn explains the patient demographic and breakdown of treatment types, noting that despite a longer median treatment duration, cyt...
|
- Details
- Pedro Barata and Cristiane Bergerot discuss the quality of life data from the non-inferiority Phase II trial of lenvatinib/everolimus combination for the treatment of renal cell carcinoma (RCC). The study compares the starting doses of lenvatinib and finds that patients treated with a higher dose of 18mg experience better health-related quality of life and disease burden control. Dr. Bergerot asse...
|
